Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593281 · ClinicalTrials.gov registry record · Phase 3
INFUSE Morphine Study
A Phase 3 study of Pain, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT00593281: Completed Phase 3 study of Pain, sponsored by Halozyme Therapeutics.
NCT00593281 is a Phase 3 study of Pain that has completed, run by Halozyme Therapeutics. The registered enrollment target is 13 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593281, a Phase 3 study of Pain, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this within-patient controlled study, each eligible study patient receives a single injection by each of the three methods of morphine administration, sequentially on three consecutive days, according to the order specified by a randomization schedule. Each of the three injections consists of 5 mg of morphine (1.0 mL of 5 mg/mL solution). The HYLENEX injection will be 1 mL of 150 units. Although the IV administration will not be blinded, the two SC injections will be double-blinded, using the same volume of normal saline (0.9% sodium chloride) placebo (1.0 mL) as HYLENEX.
Conditions Studied
Interventions
- DRUG Hylenex
Study Locations (2)
California
- UCSD Thornton Hospital - San Diego
- San Diego Hospice and Palliative Care - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-10 |
| Phase | Phase 3 |
What the finished NCT00593281 record still lists
NCT00593281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Hylenex is the first listed.
NCT00593281 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00593281 about?
NCT00593281 is a clinical study titled "INFUSE Morphine Study". Double-blind study comparing the pharmacokinetics, safety and tolerability of morphine administered subcutaneously (SC) with and without human recombinant hyaluronidase (HYLENEX) and intravenously conducted in patients in a hospice care setting or through a palliative care medicine setting. In this ...
What is the current status of trial NCT00593281?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2006-01. Estimated completion is 2006-10.
What conditions does trial NCT00593281 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT00593281?
The interventions under investigation include: Hylenex (DRUG).
Who is sponsoring clinical trial NCT00593281?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00593281 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00593281's enrollment target sits among peer trials
13 357th of 374 higher than 18 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia